-
Mersana, Janssen Biotech partner to discover new ADC product candidates
pharmaceutical-business-review
February 04, 2022
Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research...
-
CuriRx Launches the Advanced Bioprocessing and Analytical Center
contractpharma
January 26, 2022
New center allows the CDMO to further support biotherapeutic drug developers.
-
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration
prnasia
January 04, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies...
-
Genmab Gains Broad Access to Synaffix's ADC Technologies
contractpharma
January 04, 2022
Secures rights for conducting research on ADCs against multiple drug targets under new licensing agreement.
-
Emergence Therapeutics Closes €87 Million Series A Financing Round
contractpharma
December 08, 2021
Plans to advance its Nectin-4 antibody drug conjugate.
-
Abzena, BiVictriX Therapeutics Collaborate to Manufacture ADCs
ContractPharma
November 19, 2021
BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience...
-
SOTIO, LegoChem Biosciences Enter ADC License Agreement
ContractPharma
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company, entered an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc., a biotechnology company...
-
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
B3Cnewswire
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc...
-
MilliporeSigma Launches New Tech and Expanded ADC Capacity
ContractPharma
October 29, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, has launched new technology and expanded capacity to advance ADC therapies.
-
NEWS SEC-MS: a “powerful tool” for ADC analysis, find researchers
EuropeanPharmaceuticalReview
October 28, 2021
In a new study, scientists demonstrated that size exclusion chromatography (SEC) could be successfully combined with mass spectrometry (MS) to characterise antibody-drug conjugates (ADCs) on the intact molecular level.